pakistan
Tzield: US approves expanded use of type 1 diabetes drug
Key takeaways
- The FDA had first approved the drug, Tzield, in 2022 to delay the progression of type 1 diabetes from stage 2 to 3 in patients aged 8 years and older.
- In April, the regulator approved use of the drug to delay the progress to stage 3 in patients as young as one year.
- The latest label expansion allows use of the drug in children recently diagnosed with stage 3 of the condition, with the aim of slowing down loss of insulin production.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize The US Food and Drug Administration said on Friday it has approved the expanded use of Sanofi’s type 1 diabetes injection in children aged 8 to 17 years who were recently diagnosed with stage 3 of the condition.
The FDA had first approved the drug, Tzield, in 2022 to delay the progression of type 1 diabetes from stage 2 to 3 in patients aged 8 years and older. Its label was expanded over time.
In April, the regulator approved use of the drug to delay the progress to stage 3 in patients as young as one year.
Article preview — originally published by ARY News. Full story at the source.
Read full story on ARY News →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from ARY News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop